

Effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patients

Sonnal Lohia^{a,b}, Justyna Siwy^c, Emmanouil Mavrogeorgis^{b,c}, Susanne Eder^d, Stefanie Thoeni^d, Gert Mayer^d, Harald Mischak^c, Antonia Vlahou^a and Vera Jankowski^{b*}

^aCenter of Systems Biology, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece; slohia@bioacademy.gr (S.L.); vlahoua@bioacademy.gr (A.V.)

^bInstitute for Molecular Cardiovascular Research, RWTH Aachen University Hospital, 52074 Aachen, Germany; mavrogeorgis@mosaiques.de (E.M.); vjankowski@ukaachen.de (V.J.)

^cMosaiques Diagnostics GmbH, 30659 Hannover, Germany; siwy@mosaiques-diagnostics.com (J.S.); mischak@mosaiques.de (H.M.)

^dDepartment of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, 6020 Innsbruck, Austria; susanne.eder@i-med.ac.at (S.E.); stefanie.thoeni@i-med.ac.at (S.T); gert.mayer@i-med.ac.at (G.M.)

*Correspondence: vjankowski@ukaachen.de; Tel.: +49-(0241)-80-80580

Abstract:

Aim: Type II Diabetes mellitus (T2DM) accounts for approximately 90% of all DM cases in the world; and is diagnosed with increased levels of blood glucose or hyperglycemia. Glucagon-like peptide-1 receptor (GLP-1R) agonists have established an increased capability to target directly or indirectly six core defects associated with T2DM, while, the underlying molecular mechanisms of these pharmacological effects are not fully known. This exploratory study was conducted to analyze the effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patients.

Material and Methods: Urine samples of thirty-two T2DM patients from the PROVALID study (A Prospective Cohort Study in Patients with T2DM for Validation of Biomarkers) were collected at pre- and post-treatment with GLP-1R agonist drugs, and analyzed by capillary electrophoresis coupled to mass spectrometry (CE-MS).

Results: In total, 329 urinary peptides were identified, of which 70 were significantly affected by the GLP-1R agonist treatment; fragmenting from 26 different proteins. The downregulation of MMP proteases, based on the concordant downregulation of urinary collagen peptides with GLP-1R agonist treatment was highlighted in the study. Treatment also resulted in the downregulation of peptides from SERPINA1, APOC3, CD99, CPSF6, CRNN, SERPINA6, HBA2, MB, VGF, PIGR and TTR, many of which were previously found associated with increased kidney and/or vascular damage, indicating beneficial effect of GLP-1R agonists.

Conclusions: The novel findings in this study, indicate potential molecular mechanisms of GLP-1R agonists in the context of management of T2DM and prevention or delaying the progression of its associated diseases.

Keywords: T2DM, GLP-1R agonists, CE-MS, peptidomics, urine, peptide, collagen, COL1A1, COL3A1, MMP

Abstract word count: 246 words

Main text word count: 2933 words

Number of references: 52 references

Number of tables: 2 tables

Number of figures: 3 figures

Effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patients
Lohia *et al.*

1 **Introduction:**

2 In 2021, the International Diabetes Federation (IDF) predicted a five-fold increase in the
3 worldwide adult population of Diabetes mellitus, from 150 million in 2000¹ to 783 million in 2045²;
4 of which Type II Diabetes mellitus (T2DM) is said to account for approximately 90% of all cases³.
5 T2DM is characterized as a chronic disease⁴ and is diagnosed with increased levels of blood
6 glucose or hyperglycemia⁵. T2DM has been associated with macrovascular complications, such as
7 atherosclerosis, myocardial infarction and diabetic foot syndrome; as well as microvascular
8 complications, such as neuropathy, retinopathy, and nephropathy⁶⁻⁸. Approximately 44% of all
9 T2DM cases have been linked to obesity, correlating an exponential increase in their worldwide
10 prevalence^{9,10}. Additionally, the World Health Organization (WHO) predicts 57.8% of the world
11 population to be overweight and obese by 2030¹¹.

12

13 Since no cure exists, efforts to control and treat T2DM have escalated¹². The American Diabetes
14 Association (ADA) recommends healthy lifestyle changes as the first-in-line response, followed by
15 metformin-based pharmaceutical interventions¹³. The approach of lowering glucose plasma
16 levels, remains the most sought-after treatment and has recently witnessed novel and effective
17 advances. These alongside metformin, commonly include treatment with glucagon-like peptide-1
18 receptor (GLP-1R) agonists, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, dipeptidyl
19 peptidase-4 (DPP-4) inhibitors and insulin pumps followed by continuous monitoring of glucose
20 levels⁸. Furthermore, research focusing on treatment paradigms targeting the ‘ominous octet’ of
21 T2DM, implicated in the development and progression of hyperglycemia, has gained momentum
22 in the last couple of decades.

23

24 The GLP-1R agonists have dramatically transformed patient care guidelines for T2DM¹⁴. In
25 comparison to the other antihyperglycemic medications, GLP-1R agonists have established an
26 increased capability to target directly or indirectly six out of the eight core defects associated with
27 T2DM¹⁵⁻¹⁷. In response to food intake, the intestinal L-cells dependent secretion of GLP-1 is
28 significantly impaired in T2DM patients, which affects the pancreatic β cells dependent insulin
29 secretion; eventually resulting in hyperglycemia¹⁸⁻²⁰. The synthetically produced GLP-1R agonists
30 stimulate GLP-1R, in a similar fashion as the native GLP-1. Treatment benefits of peptide-based
31 GLP-1R agonists include glycemic control, weight loss, delayed onset of macroalbuminuria,
32 prevention of clinical hyperglycemic episodes and cardiovascular events, and reduced estimated
33 glomerular filtration rate (eGFR) decline; that in turn indirectly result in the inhibition of glucagon
34 secretion and increased secretion of insulin with minimal hypoglycemic risks^{8,21-23}.

35

36 Since their first approval in 2005, seven GLP-1R agonists drugs have been developed for glycemic
37 control in T2DM patients. In 2021, Trujillo *et al.*, described fourteen head-to-head trials conducted
38 on these seven GLP-1R agonists, the results of which continue to establish the benefits of this
39 class of drugs in treatment of T2DM patients. The authors further highlighted studies that have
40 published beneficial cardiovascular and renal outcomes of the treatment; however, the results, in
41 terms of the magnitude for glycemic control and adverse effects are not consistent²⁴. The focus
42 of research thus needs to shift from investigating the pharmacological effects of GLP-1R agonists,
43 to understanding the underlying molecular mechanisms. Therefore, in this exploratory study, we
44 aimed to assess the effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM
45 patients, in an untargeted peptidomics approach.

46

47 Recent advances in the analyses of urinary proteome and peptidome, have paved way for the
48 detection of alterations at both pathological as well as physiological levels in chronic diseases²⁵.
49 Urine-based omics studies have especially garnered relevance, due to the ease of sample
50 collection, longer stability of the peptides, complex composition (from blood, kidney, and bladder)
51 and the possibility of larger cohort studies because of its non-invasive approach. In addition, the
52 water soluble and charged nature of urinary peptides enable their uncomplicated mass
53 spectrometric (MS) based detections²⁶. The urinary peptidomic analysis in this study was
54 performed by a capillary electrophoresis coupled to mass spectrometry (CE-MS) technique, which
55 supports the identification of naturally occurring urinary peptides and peptidomic changes in
56 response to drug interventions²⁷.

57

58 **Materials and Methods:**

59 ***Study population and sample collection***

60 Used were urine samples of thirty-two T2DM patients, administered renin-angiotensin system
61 (RAS) inhibitor medications at the primary health care level, recruited within the Prospective
62 Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID)
63 study. PROVALID is an observational, prospective cohort study in five European countries, as
64 described previously²⁸. Consent was obtained from all the patients. Urine samples were collected
65 from T2DM patients at their visit just before GLP-1R agonists prescription (Liraglutide 1.2-6 mg/ml
66 or Exenatide 0.01-0.25 mg/ml or Lixisenatide 0.01-0.02 mg/ml) and labelled as pre-treatment
67 samples. The urine samples collected at the first visit after the treatment initiation were labelled
68 as post-treatment samples. All urine samples were stored at -20°C until analysis.

69 **Sample preparation and CE-MS analysis**

70 The standard operating protocols describing urine sample preparation and extraction of peptides
71 followed in this study, have been previously published²⁹. The CE-MS analysis was conducted as
72 described in detail by Zurbig *et al.*,³⁰ utilizing a P/ACE MDQ capillary electrophoresis system
73 (Beckman Coulter, Fullerton, CA, USA) coupled with a Micro-TOF II MS (Bruker Daltonic, Bremen,
74 Germany) instrument. Literary evidence on the advantages of CE-MS analysis in terms of
75 reproducibility, sensitivity, precision and accuracy are extensively available³¹. The relative peptide
76 intensities were normalized based on an internal standard of 29 stable collagen peptides, that can
77 be detected naturally in urine samples of healthy and diseased. This calibration was performed
78 for normalizing the variability in peptide intensities³². The resulting peptides and their normalized
79 intensity values were stored in an internal Microsoft SQL database³³, which enabled the
80 comparison of the pre- and post-treatment urinary peptide profiles. For identification of the
81 peptide sequences, MS/MS based analysis by a Dionex Ultimate 3000 RSLC nanoflow system
82 (Dionex, Camberley, UK) or a Beckman P/ACE MDQ CE that was coupled to an Orbitrap Velos MS
83 instrument (Thermo Fisher Scientific Inc., Boston, MA, USA) was performed, as described
84 previously³⁴.

85 **Statistical analysis**

86 All statistical analyses in this study were performed using R programming (R version 4.2.2, R
87 Foundation for Statistical Computing, Vienna, Austria with IDE: R Studio Version 1.2.5, Boston,
88 MA, USA). As a pre-requisite for the analysis, thresholds of 30% peptide frequency (in at least one
89 treatment group) and area under the curve (AUC) value ≥ 0.60 were applied. The normally
90 distributed and continuous datasets generated from CE-MS based peptide profiles of the urine
91 samples, obtained from pre-treatment ($n=32$) and post-treatment ($n=32$); were compared by a

92 paired Wilcoxon rank-sum test, using the `row_wilcoxon_paired()` function from the `matrixTests`
93 package. A p -value < 0.05 was considered statistically significant, which was further adjusted for
94 false discovery rates (FDR) by the Benjamini-Hochberg method³⁵. All the plots in this manuscript
95 were created using the `ggplot()` function from the `ggplot2` package.

96 ***Bioinformatic - Proteasix analysis***

97 The proteolytic events responsible for the secretion of the statistically significant urinary peptides
98 were investigated by the open-source online tool “Proteasix” (<http://www.proteasix.org>,
99 accessed on 6 March 2023). In brief, Proteasix retrieves information from literature and databases
100 like MEROPs, UniProt Knowledgebase (KB) and CutDB. The “Observed Prediction tool” of Proteasix
101 with search parameters set to default, was utilized in this study.

102

103 **Results:**

104 ***Study design***

105 The exploratory and untargeted urinary peptidomic approach in this study, was conducted to
106 analyze the effect of GLP-1R agonist treatment on the urinary peptidome of T2DM patients, as
107 illustrated in Figure 1. Briefly, urine samples from thirty-two T2DM patients were collected at two
108 time points: pre-treatment and post-treatment, with a time interval of 11.5 ± 3.72 months in
109 between. Intervention with GLP-1R agonist was introduced at 4.4 ± 4.11 months from pre-
110 treatment visit and the treatment duration until the post-treatment visit was 6.9 ± 3.59 months.

111 ***Clinical information***

112 The clinical information of all the thirty-two T2DM patients participating in this study, from pre-
113 and post-treatment visits with GLP-1R agonists are provided in the Table 1. The mean age for the
114 patients at first sample collection was 63.7 ± 7.25 years and 56.3% of them were females. As
115 depicted in the Table 1, no statistically significant difference between the clinical levels of
116 Hemoglobin A1C (HbA1C), body weight (BW), body mass index (BMI), systolic and diastolic blood
117 pressure (SBP/DBP), eGFR, albuminuria to creatinine ratio (UACR) and urinary creatinine (UCREA)
118 was observed after the treatment with GLP-1R agonists.

119 ***Peptidomic analysis***

120 Following their collection, the urine samples subjected to CE-MS analysis, generated in total sixty-
121 four urinary peptide profiles (pre-treatment, $n=32$ and post-treatment, $n=32$). The normalized
122 urinary peptide profiles were statistically analyzed by Wilcoxon-rank sum test, pair-wise (pre- and
123 post-treatment per patient). A threshold of AUC values ≥ 0.60 along with a frequency threshold
124 of 30% (i.e., ≥ 10 out of 32 datasets) in at least one treatment group, was applied to the peptide
125 data. This analysis resulted in a list of 329 sequenced peptides to be further investigated.
126 Statistical assessment including Benjamini-Hochberg FDR adjustment yielded a list of 70
127 statistically significant peptides (adjusted p -value < 0.05) affected by the GLP-1R agonist
128 treatment, detailed information of which is provided in Table S1. The distribution of peptide
129 intensity of these 70 statistically significant peptides (red spots) amongst the 329 peptides was
130 also examined (Figure 2a). Assessing the distribution in regulation of all the 329 peptides in
131 response to the treatment (Figure 2b), highlighted the downregulation of urinary peptides in the
132 majority of the statistically significant peptides (66 out of 70 peptides).

133 The 70 statistically significant peptides were identified as fragments of 26 proteins, as shown in
134 Table 2. Most of the peptides (59 out of 70) originated from the collagen family of proteins and

135 41 out of the 59 collagen peptides belonged in majority to three collagen proteins, namely,
136 collagen alpha-1(III) chain (P02461; COL3A1; $n=16$), collagen alpha-1(I) chain (P02452; COL1A1;
137 $n=15$) and collagen alpha-2(I) chain (P08123; COL1A2; $n=10$). All the remaining identified 11 (out
138 of 70) urinary peptides came from different proteins, alpha-1-antitrypsin (P01009; SERPINA1),
139 apolipoprotein C-III (P02656; APOC3), CD99 antigen (P14209; CD99), cleavage and
140 polyadenylation specificity factor subunit 6 (Q16630; CPSF6), Cornulin (Q9UBG3; CRNN),
141 corticosteroid-binding globulin (P08185; SERPINA6), hemoglobin subunit alpha (P69905; HBA1;
142 HBA2), myoglobin (P02144; MB), neurosecretory protein VGF (O15240; VGF), polymeric
143 immunoglobulin receptor (P01833; PIGR) and transthyretin (P02766; TTR). The 4 out of the 70
144 urinary peptides showing a statistically significant upregulation on treatment with GLP-1R
145 agonists in T2DM patients, as observed in Figure 2b, were characterized as COL3A1 ($n=3$) and
146 COL1A2 ($n=1$) peptides (Table 2).

147

148 Since several peptides from COL1A1 and COL3A1 were found significantly associated with
149 treatment, we investigated the alignment of the peptides in the protein structure. The respective
150 identified peptide sequences were aligned with the primary structure of the proteins, as shown
151 in Figure 3a and Figure 3c, respectively. For both proteins, peptides appeared equally distributed,
152 no specific hot spot became apparent.

153 ***Analysis of proteases***

154 To uncover plausible molecular mechanisms responsible for the observed impact of GLP-1R
155 agonists treatment on urinary peptides in T2DM patients, the proteases potentially responsible
156 for cleavage of the 70 statistically significant peptides were investigated using Proteasix. In total,
157 10 endopeptidases were retrieved as a result of the default search with the “Observed Prediction
Effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patients
Lohia *et al.*

158 tool” of Proteasix, putatively responsible for cleaving 38 urinary peptides (36 downregulated and
159 2 upregulated) out of the 70 urinary peptides. The results are provided in Table S2. Most of the
160 predicted endopeptidases belonged to the matrix metalloproteinase (MMP) family of proteases
161 (7 out of 10 proteases), responsible for cleaving peptides at both the N’ and C’ terminals. Further
162 proteases predicted as potentially responsible for cleaving the N’ terminal belonged to the
163 cathepsin family (CTSL and CTSD) while that cleaving at the C’ terminus was A disintegrin and
164 metalloproteinase with thrombospondin motifs 5 (ADAMTS5).

165 **Discussion:**

166 In the last decade, GLP-1R agonists have been the recommended and preferred second line
167 treatment for T2DM patients. Despite the various advantages of GLP-1R agonists over other anti-
168 hyperglycemic drugs, the underlying molecular mechanisms of treatment with GLP-1R agonists
169 have not been studied in-depth. Aiming to understand the effect of GLP-1R agonist treatment on
170 T2DM patients, the urinary peptidome of thirty-two T2DM patients were analyzed for the first
171 time in this study, using the CE-MS technology. The untargeted peptidomic analysis coupled with
172 statistical tools identified 70 sequenced peptide fragments from 26 proteins, as statistically
173 significantly different (adjusting for multiple testing) in abundance between the pre- and post-
174 treatment samples. Uniform distribution of intensity of the 70 peptides (red spots in Figure 2a),
175 emphasized that their observed significant change with GLP-1R agonist treatment was not a
176 function of abundance in the urine samples. For most of these 70 peptides, a comparative analysis
177 further revealed a combined downregulation with GLP-1R agonist treatment (66/70 peptides).

178

179 Along these lines, collectively, all the non-collagen peptides (11 out of 70) showed lower
180 abundance after GLP-1R agonist treatment and each was generated from a different protein
Effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patients
Lohia *et al.*

181 namely, SERPINA1, APOC3, CD99, CPSF6, CRNN, SERPINA6, HBA2, MB, VGF, PIGR and TTR. In
182 studies analyzing the effect of Liraglutide (GLP-1R agonist type) on T2DM patients, Rafiullah *et*
183 *al.*,³⁶ reported the downregulation of the urinary protein SERPINA1 and Adiels *et al.*,³⁷ reported
184 decreased secretion of APOC3, respectively with treatment. No literature was found reporting
185 regulation of CD99, CPSF6, HBA2, MB and TTR by GLP-1R agonist treatment. However, impact of
186 diabetes and/or obesity on these molecules has been reported: CD99 transcripts have been stated
187 to up-regulate in T2DM profiles³⁸; CPSF6 indirectly modulates insulin secretion³⁹; HBA2, a
188 commonly known marker for anemia and β -thalassaemia, interferes with glycemic markers of
189 T2DM patients⁴⁰. In addition, elevated levels of MB, a known cardiac marker, were reported in
190 T2DM patients⁴¹ and increased levels of TTR have been associated with glucose intolerance,
191 obesity and T2DM⁴². Benchoula *et al.*,⁴³ in their extensive review reported that VGF is expected to
192 induce obesity, while also playing a role in lipolysis and insulin secretion, hence, acting as a
193 potential target in T2DM therapy. The results in this study may therefore indicate towards the
194 further beneficial effect of GLP-1R agonists in downregulation of CD99, CPSF6, HBA2, MB, TTR and
195 VGF peptides. No evidence on the association of SERPINA6 and PIGR protein with T2DM and/or
196 GLP-1R agonists treatment could be found in the literature.

197

198 On the other hand, the remaining 59 out of the 70 statistically significant urinary peptides, majorly
199 generated from three prominent collagen proteins COL3A1 ($n=16$), COL1A1 ($n=15$) and COL1A2
200 ($n=10$). Recently, He *et al.*,⁴⁴ reported about the high abundance of collagen peptides observed in
201 urine samples, as a result of proline hydroxylation which plausibly inhibits its reabsorption in the
202 kidney. 55 out of the 59 collagen peptides were observed to be significantly downregulated with
203 GLP-1R agonists treatment in the T2DM urinary proteome, while 4 peptides (COL3A1; $n=3$ and

204 COL1A2; $n=1$) showed a significant upregulation on treatment. In-line with the extensive recent
205 report by Mavrogeorgis *et al.*,⁴⁵ all the urinary collagen peptides identified in this study were
206 devoid of the signal peptide, N-terminal pro-peptide and C-terminal pro-peptide; corresponding
207 only to the mature protein region (Figure 3a and 3c). The observed downregulation of the collagen
208 peptides in our study could potentially represent rather an attenuated degradation of the mature
209 collagen protein than resulting from protein synthesis or protein assembling processes.

210

211 To further corroborate the above speculation, endopeptidases responsible for putatively cleaving
212 the 70 statistically significant peptides were analyzed with Proteasix. The MMP family of proteases
213 accounted for cleaving the maximum statistically significant peptides (89% of the cleavage sites,
214 i.e., 34 out of the 38 urinary peptides); majorly by MMP2 (21.1%), MMP9 (21.1%) and MMP13
215 (15.5%). The suggested downregulation in the activity of MMP peptidases as observed by
216 decrease in intensity of collagen peptides in this study, is in-line with literature. Down-regulation
217 in expression of MMP9 was observed on treatment with Liraglutide in a study that included
218 induced-DM rabbit models⁴⁶. In an another study, 45% and 60% reduction in activity of MMP2
219 and MMP9, respectively, in addition to 60% reduced COL1A1 levels, was observed in a male
220 C57BL/6 mice on treatment with Semaglutide (GLP-1R agonist type)⁴⁷. Research groups exploring
221 the effect of Exenatide (GLP-1R agonist type) treatment on tumor necrosis factor (TNF)- α human
222 coronary artery smooth muscle cells⁴⁸ and human retinal pigment epithelium cells⁴⁹, reported the
223 downregulated expression of MMP2 and MMP9, respectively on treatment. Another study
224 analyzing atherosclerosis associated biomarkers in T2DM female subjects, reported decrease in
225 MMP2 and MMP9 levels, with an increase in GLP-1 and GLP-1R levels⁵⁰. Interestingly, treatment

226 of Human SW1353 with Dulaglutide (GLP-1R agonist type)⁵¹ and Fibroblast-like synoviocytes cell
227 lines with Exenatide⁵², also resulted in the downregulation of MMP13 and ADAMTS5 proteases.

228

229 To conclude, this untargeted peptidomic analysis to identify the effect of GLP-1R agonists
230 treatment on the urinary peptidome of T2DM patients, indicated as a prominent finding the
231 downregulation of MMP proteases, as identified by the downregulation of urinary collagen
232 peptides on GLP-1R agonists treatment. Treatment with GLP-1R agonists also resulted in the
233 decrease of SERPINA1, APOC3, CD99, CPSF6, CRNN, SERPINA6, HBA2, MB, VGF, PIGR and TTR
234 peptides; indicating a potential benefit as many of these proteins express increased levels in
235 T2DM patients. The results also merit the possibility of larger cohort studies to further understand
236 the underlying molecular mechanisms behind the findings.

237

238 **Acknowledgments:**

239 Author S.L. would like to extend deepest gratitude to the members of Vlahou Lab at BRFAA,
240 Greece and Mosaiques Diagnostics, Germany. Author V.J. is funded by the 'Deutsche
241 Forschungsgemeinschaft' (DFG, German Research Foundation) through the Transregional
242 Collaborative Research Centre (TRR 219; Project-ID 322900939), (subproject S-03), (INST 948/4S-
243 1); CRU 5011 project number 445703531. Authors H.M., A.V. and V.J. are funded by the Cost-
244 Action CA 21165, IZKF Multiorgan complexity in Friedreich Ataxia, CA201165.

245

246 **Conflict of Interest Statement:**

247 The authors declare no conflict of interest. Author H.M. is the founder and co-owner of Mosaiques
248 Diagnostics (Hannover, Germany). Authors E.M. and J.S. are employed by Mosaiques Diagnostics.

249

250 **Funding:**

251 This work was supported by the European Union’s Horizon 2020 research and innovation program
252 by grant No 860329 (Marie-Curie ITN “STRATEGY-CKD”) and No 848011 (“DC-ren”).

253

References:

1. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes research and clinical practice*. Apr 2018;138:271-281. doi:10.1016/j.diabres.2018.02.023
2. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes research and clinical practice*. Jan 2022;183:109119. doi:10.1016/j.diabres.2021.109119
3. Kotwas A, Karakiewicz B, Zabielska P, Wieder-Huszla S, Jurczak A. Epidemiological factors for type 2 diabetes mellitus: evidence from the Global Burden of Disease. *Archives of public health = Archives belges de sante publique*. Jun 22 2021;79(1):110. doi:10.1186/s13690-021-00632-1
4. Tinajero MG, Malik VS. An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Review. *Endocrinology and metabolism clinics of North America*. Sep 2021;50(3):337-355. doi:10.1016/j.ecl.2021.05.013
5. Schmidt AM. Highlighting Diabetes Mellitus: The Epidemic Continues. Review. *Arteriosclerosis, thrombosis, and vascular biology*. Jan 2018;38(1):e1-e8. doi:10.1161/ATVBAHA.117.310221
6. Beckman JA, Creager MA. Vascular Complications of Diabetes. Review. *Circulation research*. May 27 2016;118(11):1771-85. doi:10.1161/CIRCRESAHA.115.306884
7. Thipsawat S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature. Research Support, Non-U.S. Gov't
Review. *Diabetes & vascular disease research*. Nov-Dec 2021;18(6):14791641211058856. doi:10.1177/14791641211058856
8. Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Review. *The lancet Diabetes & endocrinology*. Aug 2021;9(8):525-544. doi:10.1016/S2213-8587(21)00113-3
9. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Meta-Analysis
Review
Systematic Review. *BMJ*. Jan 10 2012;344:d7771. doi:10.1136/bmj.d7771
10. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. *Jama*. Jan 1 2003;289(1):76-9. doi:10.1001/jama.289.1.76
11. Iqbal J, Wu HX, Hu N, et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials. Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Systematic Review. *Obesity reviews : an official journal of the International Association for the Study of Obesity*. Jun 2022;23(6):e13435. doi:10.1111/obr.13435
12. Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Review. *Molecules*. Apr 23 2020;25(8)doi:10.3390/molecules25081987
13. ElSayed NA, Aleppo G, Aroda VR, et al. 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2023. *Diabetes care*. Jan 1 2023;46(Supple 1):S10-S18. doi:10.2337/dc23-S001
Effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patients
Lohia et al.

14. Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Review. *Postgraduate medical journal*. Mar 2020;96(1133):156-161. doi:10.1136/postgradmedj-2019-137186
15. DeFronzo RA, Triplitt CL, Abdul-Ghani M, Cersosimo E. Novel Agents for the Treatment of Type 2 Diabetes. *Diabetes spectrum : a publication of the American Diabetes Association*. May 2014;27(2):100-12. doi:10.2337/diaspect.27.2.100
16. Abdul-Ghani M, DeFronzo RA. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. *Diabetes care*. Aug 2017;40(8):1121-1127. doi:10.2337/dc16-2368
17. Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Review
Video-Audio Media. *Postgraduate medicine*. Nov 2020;132(sup2):3-14. doi:10.1080/00325481.2020.1798099
18. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Lecture. *Diabetes*. Apr 2009;58(4):773-95. doi:10.2337/db09-9028
19. Taylor SI, Yazdi ZS, Beitelshes AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review. *The Journal of clinical investigation*. Jan 19 2021;131(2)doi:10.1172/JCI142243
20. Holst JJ. The physiology of glucagon-like peptide 1. Review. *Physiological reviews*. Oct 2007;87(4):1409-39. doi:10.1152/physrev.00034.2006
21. Gentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Research Support, Non-U.S. Gov't
Review. *Diabetes/metabolism research and reviews*. Jan 2019;35(1):e3070. doi:10.1002/dmrr.3070
22. Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S. GLP-1 Receptor Agonists and Kidney Protection. Review. *Medicina (Kaunas)*. May 31 2019;55(6)doi:10.3390/medicina55060233
23. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Review. *Molecular metabolism*. Apr 2021;46:101102. doi:10.1016/j.molmet.2020.101102
24. Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Review. *Therapeutic advances in endocrinology and metabolism*. 2021;12:2042018821997320. doi:10.1177/2042018821997320
25. Sirolli V, Pieroni L, Di Liberato L, Urbani A, Bonomini M. Urinary Peptidomic Biomarkers in Kidney Diseases. Review. *International journal of molecular sciences*. Dec 21 2019;21(1)doi:10.3390/ijms21010096
26. Latosinska A, Siwy J, Faguer S, Beige J, Mischak H, Schanstra JP. Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease. Research Support, Non-U.S. Gov't
Review. *Proteomics Clinical applications*. Jan 2021;15(1):e2000027. doi:10.1002/prca.202000027
27. Siwy J, Klein T, Rosler M, von Eynatten M. Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial. Clinical Trial, Phase III

Randomized Controlled Trial

Effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patients
Lohia *et al.*

Research Support, Non-U.S. Gov't. *Proteomics Clinical applications*. Mar 2019;13(2):e1800144. doi:10.1002/prca.201800144

28. Eder S, Leierer J, Kerschbaum J, et al. A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics. *Kidney & blood pressure research*. 2018;43(1):181-190. doi:10.1159/000487500

29. Haubitz M, Good DM, Woywodt A, et al. Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Research Support, N.I.H., Extramural

Research Support, Non-U.S. Gov't. *Molecular & cellular proteomics : MCP*. Oct 2009;8(10):2296-307. doi:10.1074/mcp.M800529-MCP200

30. Zurbig P, Renfrow MB, Schiffer E, et al. Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Research Support, N.I.H., Extramural. *Electrophoresis*. Jun 2006;27(11):2111-25. doi:10.1002/elps.200500827

31. Mischak H, Vlahou A, Ioannidis JP. Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Research Support, Non-U.S. Gov't

Review. *Clinical biochemistry*. Apr 2013;46(6):432-43. doi:10.1016/j.clinbiochem.2012.09.025

32. Jantos-Siwj J, Schiffer E, Brand K, et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. Research Support, Non-U.S. Gov't. *Journal of proteome research*. Jan 2009;8(1):268-81. doi:10.1021/pr800401m

33. Schanstra JP, Zurbig P, Alkhalaf A, et al. Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. Clinical Trial

Multicenter Study

Research Support, Non-U.S. Gov't. *Journal of the American Society of Nephrology : JASN*. Aug 2015;26(8):1999-2010. doi:10.1681/ASN.2014050423

34. Klein J, Papadopoulos T, Mischak H, Mullen W. Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine. Research Support, Non-U.S. Gov't. *Electrophoresis*. Apr 2014;35(7):1060-4. doi:10.1002/elps.201300327

35. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. *J R Stat Soc B*. 1995;57(1):289-300. doi:DOI 10.1111/j.2517-6161.1995.tb02031.x

36. Rafiullah M, Benabdelkamel H, Masood A, et al. Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment. *Current issues in molecular biology*. Feb 6 2023;45(2):1407-1421. doi:10.3390/cimb45020092

37. Adiels M, Taskinen MR, Bjornson E, et al. Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia. Randomized Controlled Trial

Research Support, Non-U.S. Gov't. *Diabetes, obesity & metabolism*. Aug 2019;21(8):1861-1870. doi:10.1111/dom.13744

38. Marques ES, Formato E, Liang W, Leonard E, Timme-Laragy AR. Relationships between type 2 diabetes, cell dysfunction, and redox signaling: A meta-analysis of single-cell gene expression of human pancreatic alpha- and beta-cells. Meta-Analysis. *Journal of diabetes*. Jan 2022;14(1):34-51. doi:10.1111/1753-0407.13236

39. Yang K, Sun J, Zhang Z, Xiao M, Ren D, Liu SM. Reduction of mRNA m(6)A associates with glucose metabolism via YTHDC1 in human and mice. *Diabetes research and clinical practice*. Mar 4 2023;198:110607. doi:10.1016/j.diabres.2023.110607

Effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patients
Lohia et al.

40. Gluvic Z, Obradovic M, Lackovic M, et al. HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review. Case Reports Review. *Journal of clinical pharmacy and therapeutics*. Apr 2020;45(2):379-383. doi:10.1111/jcpt.13073
41. Odum EP, Young EE. Elevated cardiac troponin I, creatine kinase and myoglobin and their relationship with cardiovascular risk factors in patients with type 2 diabetes. *Diabetes & metabolic syndrome*. Apr-Jun 2018;12(2):141-145. doi:10.1016/j.dsx.2017.12.001
42. Pandey GK, Balasubramanyam J, Balakumar M, et al. Altered Circulating Levels of Retinol Binding Protein 4 and Transthyretin in Relation to Insulin Resistance, Obesity, and Glucose Intolerance in Asian Indians. Research Support, Non-U.S. Gov't. *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*. Aug 2015;21(8):861-9. doi:10.4158/EP14558.OR
43. Benchoula K, Parhar IS, Hwa WE. The molecular mechanism of vgf in appetite, lipids, and insulin regulation. Research Support, Non-U.S. Gov't Review. *Pharmacological research*. Oct 2021;172:105855. doi:10.1016/j.phrs.2021.105855
44. He T, Pejchinovski M, Mullen W, Beige J, Mischak H, Jankowski V. Peptides in Plasma, Urine, and Dialysate: Toward Unravelling Renal Peptide Handling. Research Support, Non-U.S. Gov't. *Proteomics Clinical applications*. Jan 2021;15(1):e2000029. doi:10.1002/prca.202000029
45. Mavrogeorgis E, Mischak H, Latosinska A, et al. Collagen-Derived Peptides in CKD: A Link to Fibrosis. Research Support, Non-U.S. Gov't. *Toxins*. Dec 23 2021;14(1)doi:10.3390/toxins14010010
46. Ding HX, Dong NX, Zhou CX, et al. Liraglutide Attenuates Restenosis After Vascular Injury in Rabbits With Diabetes Via the TGF-beta/Smad3 Signaling Pathway. *Alternative therapies in health and medicine*. Sep 2022;28(6):22-28.
47. Cardoso LEM, Marinho TS, Martins FF, Aguila MB, Mandarin-de-Lacerda CA. Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice. *Life sciences*. Apr 15 2023;319:121502. doi:10.1016/j.lfs.2023.121502
48. Gallego-Colon E, Klych-Ratuszny A, Kosowska A, et al. Exenatide modulates metalloproteinase expression in human cardiac smooth muscle cells via the inhibition of Akt signaling pathway. *Pharmacological reports : PR*. Feb 2018;70(1):178-183. doi:10.1016/j.pharep.2017.10.003
49. Garczorcz W, Gallego-Colon E, Kosowska A, et al. Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-alpha stimulated human retinal pigment epithelial cells. *Pharmacological reports : PR*. Feb 2019;71(1):175-182. doi:10.1016/j.pharep.2018.10.003
50. Dehghan F, Soori R, Gholami K, et al. Purslane (Portulaca oleracea) Seed Consumption And Aerobic Training Improves Biomarkers Associated with Atherosclerosis in Women with Type 2 Diabetes (T2D). Research Support, Non-U.S. Gov't. *Scientific reports*. Dec 5 2016;6:37819. doi:10.1038/srep37819
51. Li H, Chen J, Li B, Fang X. The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type II collagen and aggrecan in human SW1353 chondrocytes. *Chemico-biological interactions*. May 1 2020;322:108968. doi:10.1016/j.cbi.2020.108968
52. Tao Y, Ge G, Wang Q, et al. Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. Research Support, Non-U.S. Gov't. *IUBMB life*. Jul 2019;71(7):969-977. doi:10.1002/iub.2031

Tables:

Table 1: Clinical information of the T2DM patients in mean \pm SD; from pre- and post-treatment with GLP-1R agonists

<i>Clinical information</i>	T2DM patients (n=32)		<i>p</i> -value
	<i>Pre-treatment</i>	<i>Post-treatment</i>	
Age (years)	63.7 \pm 7.25		
Sex (% Females)	56.3		
HbA1C (%)	8.0 \pm 1.38	8.0 \pm 1.45	0.731
BW (kg)	98.3 \pm 16.13	98.8 \pm 20.28	0.771
BMI (kg/m ²)	33.2 \pm 6.28	33.2 \pm 6.93	0.915
SBP (mmHg)	139.2 \pm 14.35	137.1 \pm 12.61	0.385
DBP (mmHg)	81.1 \pm 7.74	81.3 \pm 8.21	0.906
eGFR (ml/min/1.73m ²)	67.7 \pm 14.46	67.6 \pm 15.55	0.965
UACR (mg/g)	33.6 \pm 58.55	25.5 \pm 44.80	0.248
UCREA (mg/dl)	103.9 \pm 41.58	96.6 \pm 50.72	0.429

HbA1C: Hemoglobin A1C; BW: Body weight; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; eGFR: estimated glomerular filtration rate; UACR: Albuminuria to Creatinine ratio; UCREA: Urinary Creatinine

Table 2: List of 26 proteins yielding the 70 statistically significant urinary peptides, in response to GLP-1R agonists treatment. (\downarrow refers to down regulation and \uparrow refers to upregulation)

UniProt ID	Gene Symbol	Protein Name	Number of peptides	
			<i>Total</i>	<i>Regulation after treatment</i>
P02461	COL3A1	Collagen alpha-1(III) chain	16	\downarrow (13) + \uparrow (3)
P02452	COL1A1	Collagen alpha-1(I) chain	15	\downarrow
P08123	COL1A2	Collagen alpha-2(I) chain	10	\downarrow (9) + \uparrow (1)
P02458	COL2A1	Collagen alpha-1(II) chain	3	\downarrow
P02462	COL4A1	Collagen alpha-1(IV) chain	2	\downarrow
P05997	COL5A2	Collagen alpha-2(V) chain	2	\downarrow
P12107	COL11A1	Collagen alpha-1(XI) chain	2	\downarrow
P27658	COL8A1	Collagen alpha-1(VIII) chain	1	\downarrow
Q5TAT6	COL13A1	Collagen alpha-1(XIII) chain	1	\downarrow
Q05707	COL14A1	Collagen alpha-1(XIV) chain	1	\downarrow
Q07092	COL16A1	Collagen alpha-1(XVI) chain	1	\downarrow
P39060	COL18A1	Collagen alpha-1(XVIII) chain	1	\downarrow
P25067	COL8A2	Collagen alpha-2(VIII) chain	1	\downarrow
P29400	COL4A5	Collagen alpha-5(IV) chain	1	\downarrow
Q14031	COL4A6	Collagen alpha-6(IV) chain	1	\downarrow
P01009	SERPINA1	Alpha-1-antitrypsin	1	\downarrow

P02656	APOC3	Apolipoprotein C-III	1	↓
P14209	CD99	CD99 antigen	1	↓
Q16630	CPSF6	Cleavage and polyadenylation specificity factor subunit 6	1	↓
Q9UBG3	CRNN	Cornulin	1	↓
P08185	SERPINA6	Corticosteroid-binding globulin	1	↓
P69905	HBA1; HBA2	Hemoglobin subunit alpha	1	↓
P02144	MB	Myoglobin	1	↓
O15240	VGF	Neurosecretory protein VGF	1	↓
P01833	PIGR	Polymeric immunoglobulin receptor	1	↓
P02766	TTR	Transthyretin	1	↓

Legends to Figures:

Figure 1: Urine samples from thirty-two T2DM patients were collected at two time points; pre-treatment and post-treatment with the intervention of GLP-1R agonists at 4.4 ± 4.11 months from first sample collection. Naturally occurring urinary peptides were quantified in the urine samples by CE-MS analysis, followed by statistical and bioinformatic analysis of the CE-MS generated urinary peptide profiles.

Figure 2: (a) Distribution of peptide intensity for all the 329 sequenced urinary peptides identified in this study. (b) Volcano plot depicting the distribution in regulation of the 329 peptides in response to GLP-1R agonist treatment. (c) The distribution of the 70 statistically significant urinary peptide profiles in pre- and post-treatment of T2DM patients, as obtained from CE-MS analysis.

Figure 3: (a) Alignment of identified peptide sequences in this study in the primary structure of protein COL1A1. (b) Box and Whisker plots depicting the down-regulation of all the COL1A1 peptides, in response to GLP-1R agonists treatment. (c) Alignment of identified peptide sequences in this study in the primary structure of protein COL3A1. (d) Box and Whisker plots depicting the up- and down-regulation of all the COL3A1 peptides, in response to GLP-1R agonists treatment. In (a) and (c), the amino acids in green and red depict the down-regulated and up-regulated peptide sequences, respectively.

Figures:




Figure 1




Figure 2




Figure 3